Announcement • Feb 04
Biotech Acquisition Company(NasdaqCM:BIOT) dropped from NASDAQ Composite Index Biotech Acquisition Company has been removed from NASDAQ Composite Index . Announcement • Jan 12
Biotech Acquisition Company Receives Non-Compliance Notice From Nasdaq On January 9, 2023, Biotech Acquisition Company (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), due to the Company’s failure to hold an annual meeting of shareholders for the fiscal year ended December 31, 2021. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Capital Market. The Notice states that the Company has until February 23, 2023 to submit a plan to regain compliance with Listing Rule 5620(a). The Company intends to submit a plan to regain compliance with Listing Rule 5620(a) within the required timeframe. If Nasdaq accepts the Company’s plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the fiscal year end, or until June 29, 2023, to evidence compliance with Listing Rule 5620(a). If Nasdaq does not accept the Company’s plan, the Company will have the opportunity to appeal the decision in front of a Nasdaq Hearings Panel. Announcement • Nov 15
Biotech Acquisition Company announced delayed 10-Q filing On 11/14/2022, Biotech Acquisition Company announced that they will be unable to file their next 10-Q by the deadline required by the SEC.